Once Daily Psoriasis Pill from Takeda Enters Priority FDA Review with a Decision Expected in Early 2027

Takeda’s once-daily psoriasis pill zasocitinib, entered FDA Priority Review with a target decision date in the first quarter of 2027.

Have A Referral?